Eliglustat
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 141 publications
The SGLT2 Inhibitor Dapagliflozin Disrupts the Cell Cycle at High Concentrations Without Altering Glycosphingolipid (De Novo)Biosynthesis.
Journal: International journal of molecular sciences
Published: August 20, 2025
Cytokine-driven glycosphingolipid metabolism modulates endoplasmic reticulum calcium homeostasis in primary human renal mesangial cells.
Journal: Frontiers in immunology
Published: August 19, 2025
Bone involvement in Gaucher disease: Data from a North African registry.
Journal: Reumatologia clinica
Published: July 17, 2025
Increased Lyso-Gb1 Levels in an Obese Splenectomized Gaucher Disease Type 1 Patient Treated with Eliglustat: Unacknowledged Poor Compliance or Underlying Factors.
Journal: Metabolites
Published: May 22, 2025
Exploring the hub gene CERS6 as a therapeutic target in type 1 diabetes through a bioinformatics and network analyst approach.
Journal: Scientific reports
Published: April 10, 2025
Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics.
Journal: Pharmacogenomics
Published: April 07, 2025
In Vivo Accumulation of Regulatory T Cells Using Eliglustat-Loaded Cryogels.
Journal: Advanced healthcare materials
Published: March 22, 2025
Eliglustat substrate reduction therapy in children with Gaucher disease type 1.
Journal: Frontiers in pediatrics
Published: December 10, 2024
Model-informed repurposing of eliglustat for treatment and prophylaxis of Shiga toxin-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) in children.
Journal: Pediatric nephrology (Berlin, Germany)
Published: December 03, 2024
Eliglustat and cardiac comorbidities in Gaucher disease: a pharmacogenomic approach to safety and efficacy.
Journal: Frontiers in medicine
Published: November 26, 2024
Challenges in Gaucher disease: Perspectives from an expert panel.
Journal: Molecular genetics and metabolism
Published: September 28, 2024
UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research.
Journal: Drug design, development and therapy
Published: September 21, 2024
Last Updated: 02/24/2026